Spectral AI wins FDA De Novo clearance for DeepView® System, enabling U.S. sales

Filed May 26, 2026 · Period ending May 26, 2026 · ~1 min read

Key Changes

• high

  FDA granted De Novo Classification for DeepView® System, a regulatory pathway for novel medical devices without existing predicates. This authorization allows Spectral AI to begin commercial distribution in the United States.

  Item 7.01 Press Release verify on EDGAR →
• high

  De Novo clearance is a significant regulatory milestone that opens the door to revenue generation from DeepView® in the U.S. market, previously unavailable to the company.

  8-K Event Analysis view on EDGAR →